Paper41585138
The roles of CD24-Sec14 like lipid binding 2 (SEC14L2) axis in the neoplastic progression of oral squamous cell carcinomas.
Chang SR and 6 others. J Dent Sci, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. The roles of CD24-Sec14 like lipid binding 2 (SEC14L2) axis in the neoplastic progression of oral squamous cell carcinomas. Papers, record 41585138. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41585138
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The roles of CD24-Sec14 like lipid binding 2 (SEC14L2) axis in the neoplastic progression of oral squamous cell carcinomas.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16824727 | CD24 plays an important role in the carcinogenesis process of the pancreas. | Biomed Pharmacother | 2006 | https://conductscience.org/library/papers/16824727 | PubMed |
| 2 | 37664387 | Utility of CD44/CD24 in the Outcome and Prognosis of Oral Squamous Cell Carcinoma: A Systematic Review. | Cureus | 2023 | https://conductscience.org/library/papers/37664387 | PubMed |
| 3 | 37598003 | Modulating Treg stability to improve cancer immunotherapy. | Trends Cancer | 2023 | https://conductscience.org/library/papers/37598003 | PubMed |
| 4 | 1319065 | Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. | Proc Natl Acad Sci U S A | 1992 | https://conductscience.org/library/papers/1319065 | PubMed |
| 5 | 38313430 | Surprising magic of CD24 beyond cancer. | Front Immunol | 2023 | https://conductscience.org/library/papers/38313430 | PubMed |
| 6 | 34434192 | Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. | Front Immunol | 2021 | https://conductscience.org/library/papers/34434192 | PubMed |
| 7 | 18413748 | Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. | Cancer Res | 2008 | https://conductscience.org/library/papers/18413748 | PubMed |
| 8 | 38881902 | From mechanism to therapy: the journey of CD24 in cancer. | Front Immunol | 2024 | https://conductscience.org/library/papers/38881902 | PubMed |
| 9 | 37021226 | miR-146a participates in the regulation of cancer stemness of oral carcinoma cells. | J Dent Sci | 2023 | https://conductscience.org/library/papers/37021226 | PubMed |
| 10 | 31406301 | CD24 - a novel 'don't eat me' signal. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/31406301 | PubMed |
| 11 | 38622125 | Single cell analysis unveils B cell-dominated immune subtypes in HNSCC for enhanced prognostic and therapeutic stratification. | Int J Oral Sci | 2024 | https://conductscience.org/library/papers/38622125 | PubMed |
| 12 | 39233744 | Risk Factors of Oral Squamous Cell Carcinoma with Special Emphasis on Areca Nut Usage and Its Association with Clinicopathological Parameters and Recurrence. | Int J Surg Oncol | 2024 | https://conductscience.org/library/papers/39233744 | PubMed |
| 13 | 37711538 | Expression of CD24 as Cancer Stem Cell Marker in the Diagnosis of Oral Squamous Cell Carcinoma - A Prospective Study. | Ann Maxillofac Surg | 2023 | https://conductscience.org/library/papers/37711538 | PubMed |
| 14 | 23511563 | Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. | Br J Cancer | 2013 | https://conductscience.org/library/papers/23511563 | PubMed |
| 15 | 21710320 | CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. | Cell Mol Life Sci | 2012 | https://conductscience.org/library/papers/21710320 | PubMed |
| 16 | 24302991 | miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes. | PLoS One | 2013 | https://conductscience.org/library/papers/24302991 | PubMed |
| 17 | 31345390 | Establishment of syngeneic murine model for oral cancer therapy. | Oral Oncol | 2019 | https://conductscience.org/library/papers/31345390 | PubMed |
| 18 | 27853649 | CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells. | Oncoimmunology | 2016 | https://conductscience.org/library/papers/27853649 | PubMed |
| 19 | 36341328 | Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer. | Front Immunol | 2022 | https://conductscience.org/library/papers/36341328 | PubMed |
| 20 | 39223142 | The disruption of NEAT1-miR-125b-5p-SLC1A5 cascade defines the oncogenicity and differential immune profile in head and neck squamous cell carcinoma. | Cell Death Discov | 2024 | https://conductscience.org/library/papers/39223142 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41585138
GET https://conductscience.org/api/papers/v1/41585138/references?page=2